top of page
  • Active, not recruiting
    • Dec 3, 2019

NCT03836053: Phase 1b - AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma AMG420

Updated: Sep 2, 2022

AMG 420


AMG420

To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as a 28-day continuous iV infusion.


Sponsor

Amgen


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT03836053


Official Title: A Phase 1b Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma

First Posted : February 11, 2019


Click here for details on ClinicalTrials.gov